Pharmaceutical Executive April 2013

April 2013 | Volume 0, Issue 0
From the Editor
The conversation thread that binds this month's Pharm Exec is building communities—when the harsh economics of market change suddenly discounts the familiar, then the best way to move up is to reach out.
The European Union's attempt to update its transparency rules sparks new debate.
Take a page from the consumer marketing playbook and promote a product's advantage and why it should matter to the customer.
Do Big Pharma dollars make physicians lousy caregivers?
There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices.
List pricing strategies that diverge from these approaches without "hitting the cliff".
The slow evolution toward a state of grace in tracking ROI for digital promotion.
By Pharmaceutical Executive Editors
Improving the quality of clinical trials is a major strategic activity for Big Pharma, one where efficient management of a demanding set of regulatory requirements can have a positive impact on the bottom line.
Pharm Exec's annual look at the trends and best practices in biopharm licensing and M&A for the year ahead.
This year's HBA Woman of the Year is Merck's Bridgette Heller of Merck Consumer Care.
Country Report
By Pharmaceutical Executive Editors
Belgium is a hub for clinical trials, a leader in the biopharmaceutical industry, and a center for pharmaceutical production and distribution.
lorem ipsum